Interview with Brian Caveney of LabCorp
Q: What need is LabCorp addressing?
A: The timeless issues LabCorp continues to address are those related to delivering world-class diagnostics solutions, bringing innovative medicines to patients faster and using technology to improve the delivery of healthcare.
read moreInterview with Don Brown of LifeOmic
Q: What need is LifeOmic addressing?
A: Precision Medicine requires the aggregation of huge data sets, including data representing individual patients from the level of their genomes all the way up through various levels of their phenomes.
read moreInterview with Myla Lai-Goldman of GeneCentric Therapeutics
Q: GeneCentric employs Drug Response Biomarkers developed via the Cancer Subtyping Platform (CSP). What makes your approach of biomarker development unique?
A: By applying CSPTM technology, GeneCentric is developing universal drug response biomarkers to enable more effective and efficient drug development informed by high resolution, genomic-defined cancer subtypes.
read moreInterview with Derek Jantz of Precision BioSciences
Q: What need is Precision BioSciences addressing?
A: Precision’s ARCUS genome editing technology is a proprietary, non-CRIPSR platform that has applications across cell therapy, gene therapy, and agriculture. We are able to edit everything from plants to primates, so prioritizing projects is an imporant part of what we do.
read moreInterview with Honoree Mary Relling, PMWC Duke 2018 Luminary Honoree
Q: Why is preemptive pharmacogenetics testing important in the context of personalized medicine?
A: We estimated that pharmacogenetic test results can impact the use of nearly 100 drugs, accounting for up to 18% of current prescriptions. Therefore, having pharmacogenetic test results already “in hand” at the time of prescribing will be more convenient for patients and physicians compared to performing as needed, one gene-at-a-time testing, which will be slower and more expensive.
read moreInterview with Eric Perakslis of Datavant
Q: What need is Datavant addressing?
A: While the volume of health data grows precipitously year over year, our ability to make use of that data is not keeping pace. There are many aspects to the inherent challenges and opportunities of this data explosion but of particular concern is the increased fragmentation.
read moreAll of Us Research Program Aims to Create Diverse Research Data Resource
In the age of big DNA data, it is important to remember that accumulating large amounts of data is not enough. Equally important is keeping the DNA data that participants provide as diverse as possible to allow us to generate answers to questions about how different variables impact people differently.
read moreInterview with Philip Parks of Exact Sciences Corporation
Q: What need is Exact Sciences Corporation addressing?
A: Exact Sciences’ mission is to improve patient outcomes through the early detection of cancer. We are especially focused on developing highly accurate, minimally invasive screening tests and technologies.
read moreInterview with Mike Nall of Biocept, Inc.
Q: What need is Biocept, Inc addressing?
A: Physicians are not receiving all the genomic information needed for precision medicine therapeutic decision making so some patients potentially miss out on targeted therapies that could save or extend their lives.
read moreInterview with Michael Pellini of Section 32
Q: How do you select startup companies you invest in? What are values you are looking for both in the companies and the leadership teams?
A: This answer is more of a philosophical one rather than a simple listing of ingredients, even though the latter might be easier or more reassuring for an entrepreneur to digest.
read more
